Computational studies for pre-evaluation of pharmacological profile of gut microbiota-produced gliclazide metabolites
<i>In silico</i> study revealed that hydroxylated gut microbiota-produced gliclazide metabolites should be further investigated as potential drug candidates with improved characteristics compared to parent drug. Moreover, their part in the therapeutic effects of gliclazide should be additionally studied <i>in vivo</i>, in order to elucidate the role of gut microbiota in gliclazide pharmacology, namely from the perspective of personalized medicine.
Authors
- Hani Al‐Salami (ORCID: https://orcid.org/0000-0003-0049-6969)
- Nebojša Pavlović (ORCID: https://orcid.org/0000-0002-9444-5830)
- Bojan Stanimirov (ORCID: https://orcid.org/0000-0002-0708-3182)
- Momir Mikov (ORCID: https://orcid.org/0000-0002-2804-0624)
- Maja Đanić (ORCID: https://orcid.org/0000-0002-7785-0666)
- Dragana Zaklan (ORCID: https://orcid.org/0000-0002-7186-3212)
- Slavica Lazarević (ORCID: https://orcid.org/0000-0002-8191-4095)
Institutions
- University of Novi Sad (RS)
- Curtin University (AU)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3389/fphar.2024.1492284
- Citations
- 6
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja